Consumer access to clozapine in Australia: how does this compare to New Zealand and the United Kingdom?

Background: Clozapine is an antipsychotic medication used in treatment resistant schizophrenia. However, clozapine is associated with a significant adverse effect profile and extensive monitoring is required to optimise consumer safety. Traditionally, clozapine can only be prescribed by a psychiatri...

Descripción completa

Detalles Bibliográficos
Publicado en:Pharmacy Practice (1886-3655) Vol. 14; no. 2; pp. 1 - 10
Autores principales: KNOWLES, Sally-Anne, MCMILLAN, Sara S., WHEELER, Amanda J.
Formato: research tables/charts Journal Article
Publicado: Centro de Investigaciones y Publicaciones Farmaceuticas S.L. 2016
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=116782644&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 116782644
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        1885642X
        3EAU
      jtl: Pharmacy Practice (1886-3655)
      issn: 1885642X
      maglogo: N
    pubinfo:
      dt: 2016
      vid: 14
      iid: 2
      pid: 36266
      pub: Centro de Investigaciones y Publicaciones Farmaceuticas S.L.
    artinfo:
      ui:
        116782644
        116782644
        116782644
        10.18549/PharmPract.2016.02.722
        116782644
      ppf: 1
      ppct: 9
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Consumer access to clozapine in Australia: how does this compare to New Zealand and the United Kingdom?
      aug:
        au:
          KNOWLES, Sally-Anne
          MCMILLAN, Sara S.
          WHEELER, Amanda J.
        affil: Griffith University, Nathan, QLD (Australia)
      sug:
        subj:
          Clozapine Therapeutic Use
          Schizophrenia Drug Therapy
          Health Services Accessibility Australia
          Clozapine Supply and Distribution
          Australia
          Medication Systems Australia
          New Zealand
          United Kingdom
          Human
          Thematic Analysis
          Surveys
          Comparative Studies
          Descriptive Statistics
          Interviews
          Pharmacists Education
          Community Health Services
          Clozapine Adverse Effects
      ab: Background: Clozapine is an antipsychotic medication used in treatment resistant schizophrenia. However, clozapine is associated with a significant adverse effect profile and extensive monitoring is required to optimise consumer safety. Traditionally, clozapine can only be prescribed by a psychiatrist and dispensed at a hospital or hospital affiliated pharmacy in Australia. These restrictions could result in significant treatment burden for consumers taking clozapine. Objective: To identify (1) the different models of supply that exist for people living in the community taking clozapine in Australia and compare to those in New Zealand and the United Kingdom, and (2) explore how these supply models may impact on consumer burden from the perspective of professionals involved in the supply of clozapine. Method: Key informants were interviewed (n=8) from Australia, New Zealand and the United Kingdom regarding how consumers, who lived in the community, accessed clozapine. Data were analysed and led to the development of four clozapine supply models. These four models were further validated by an online survey of a wider sample (n=30). Data were analysed thematically and via simple descriptive statistics. Results: Clozapine supply varied depending on location. A secondary care model was utilised in the United Kingdom compared to a community based (primary care) model in New Zealand; Australia utilised a mixture of both secondary and primary care. A key theme from all study participants was that community pharmacy should be utilised to dispense clozapine to consumers living in the community, provided adequate training and safeguards are in place. It was noted that the utilisation of community pharmacies could improve access and flexibility, thereby reducing treatment burden for these consumers. Conclusion: There are predominately two models for supply of clozapine to consumers living in the community in Australia, New Zealand and the United Kingdom. One model utilises secondary care facilities and the other community services. Community pharmacy is ideally placed to increase access to clozapine for consumers living in the community, provided appropriate training and support is given to pharmacists providing this professional service.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N